Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti‐VEGF/TKI and immunotherapy
Authors:
- 30 July 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 76 (4) , 1203-1218
Abstract
Hepatocellular carcinoma remains a global health challenge affecting close to 1 million cases yearly. Liver transplantation provides the best long‐term outcomes for those meeting strict criteria. Efforts have been made to expand these criteria, whereas others have attempted downstaging approaches. Although locoregional approaches to downstaging are appealing and have demonstrated efficacy, limitations and challenges exists including poor imaging modality to assess response and appropriate endpoints along the process. Recent advances in systemic treatments including immune checkpoint inhibitors alone or in combination with tyrosine kinase inhibitors have prompted the discussion regarding their role for downstaging disease prior to transplantation. Here, we provide a review of prior locoregional approaches for downstaging, new systemic agents and their role for downstaging, and finally, key and critical considerations of the assessment, endpoints, and optimal designs in clinical trials to address this key question.Keywords
Funding Information
- Instituto de Salud Carlos III (PI044031, PI18)
- National Comprehensive Cancer Network
This publication has 82 references indexed in Scilit:
- Sorafenib Combined with Locoregional Therapy Prior to Liver Transplantation for Hepatocellular Carcinoma: An Update on a Previous Case ReportJournal of Gastrointestinal Cancer, 2012
- Treating Hepatocellular Carcinoma With Sorafenib in Liver Transplant Patients: An Initial ExperienceTransplantation Proceedings, 2010
- Multifaceted Perspective of the Waiting List for Liver Transplantation: the Value of Pharmacokinetic ModelsHepatology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF‐Expanded Criteria Based on Preoperative ImagingAmerican Journal of Transplantation, 2007
- Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Before Liver Transplantation: A Prospective Study with Histopathologic ComparisonAmerican Journal of Roentgenology, 2006
- Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteriaLiver Transplantation, 2002
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001
- Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact SurvivalHepatology, 2001
- Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with CirrhosisNew England Journal of Medicine, 1996